

PATIENT


Name: Lynx Dx Patient
DOB: 02/09/1963
MRN: REQ000000

SPECIMEN

Collection Date: 08/09/2022
Receive Date: 08/11/2022
Result Date: 08/16/2022
Order Number: SO00000

ORDERING PHYSICIAN

Physician: Dr. John Smith
Clinic: Alaska Urology
Address: 123 Snow Storm Street
Anchorage, AK 12345



RANGES

Low Risk: 0% – 7.5%
Elevated Risk: ≥ 7.6%

RISK ASSESSMENT FACTORS*

Age: 59
Family History: No
African Ancestry: Yes
Abnormal DRE: No
Previous Biopsy: No
PSA: 5.7 ng/mL
Prostate Volume: 40 cc
PSA Density: 0.14 ng/mL/cc

*Risk Assessment Factors are included in the calculation of MPS2 when their inclusion increases the diagnostic accuracy of the results.

Risk category: Low

Likelihood of Clinically Significant Cancer Grade Group 2 or higher: 4.1%

Test Description:

MyProstateScore 2.0 (MPS2) measures 18 urinary biomarkers* to predict the percent likelihood of detecting clinically-significant prostate cancer (Grade Group [GG] ≥2, also termed Gleason score ≥7) on biopsy. For those who are biopsy naïve, a score of >7.5% is reported as elevated risk. For those patients with a prior negative biopsy, a score of >5.4% is reported as elevated risk.

*T2:ERG, SCHLAP1, OR51E2, APOC1, PCAT14, CAMKK2, PCA3, NKAIN1, B3GNT6, TFF3, SPON2, PCGEM1, TRGV9, TMSB15A, ERG, KLK3, KLK4, HOXC6

Disclaimer:

This test was developed, and its performance characteristics determined by Lynx Dx, Inc. This test is intended to assist clinical decision making related to the need for a prostate biopsy. Definitive diagnosis of prostate cancer can only be confirmed through a prostate biopsy. This test has not been cleared nor approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendment of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing.

CLIA Director: Dr. John Kitchen; CLIA Number: 23D2182199

Performing site: Lynx Dx, Inc., 5230 S. State Rd., Ann Arbor, MI 48108

PATIENT


Name: Lynx Dx Patient
DOB: 11/02/1966
MRN: REQ000000

SPECIMEN

Collection Date: 06/23/2022
Receive Date: 06/25/2022
Result Date: 06/30/2022
Order Number: SO00000

ORDERING PHYSICIAN

Physician: Dr. John Smith
Clinic: Alaska Urology
Address: 123 Snow Storm Street
Anchorage, AK 12345



RANGES

Low Risk: 0% – 7.5%
Elevated Risk: ≥ 7.6%

RISK ASSESSMENT FACTORS*

Age: 58
Family History: Yes
African Ancestry: No
Abnormal DRE: No
Previous Biopsy: No
PSA: 6.1 ng/mL
Prostate Volume: 37 cc
PSA Density: 0.16 ng/mL/cc

*Risk Assessment Factors are included in the calculation of MPS2 when their inclusion increases the diagnostic accuracy of the results.

Risk category: Elevated

Likelihood of Clinically Significant Cancer Grade Group 2 or higher: 42.6%

Test Description:

MyProstateScore 2.0 (MPS2) measures 18 urinary biomarkers* to predict the percent likelihood of detecting clinically-significant prostate cancer (Grade Group [GG] ≥2, also termed Gleason score ≥7) on biopsy. For those who are biopsy naïve, a score of >7.5% is reported as elevated risk. For those patients with a prior negative biopsy, a score of >5.4% is reported as elevated risk.

*T2:ERG, SCHLAP1, OR51E2, APOC1, PCAT14, CAMKK2, PCA3, NKAIN1, B3GNT6, TFF3, SPON2, PCGEM1, TRGV9, TMSB15A, ERG, KLK3, KLK4, HOXC6

Disclaimer:

This test was developed, and its performance characteristics determined by Lynx Dx, Inc. This test is intended to assist clinical decision making related to the need for a prostate biopsy. Definitive diagnosis of prostate cancer can only be confirmed through a prostate biopsy. This test has not been cleared nor approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendment of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing.

CLIA Director: Dr. John Kitchen; CLIA Number: 23D2182199

Performing site: Lynx Dx, Inc., 5230 S. State Rd., Ann Arbor, MI 48018

PATIENT


Name: Lynx Dx Patient
DOB: 10/11/1955
MRN: REQ000000

SPECIMEN

Collection Date: 12/17/2022
Receive Date: 12/19/2022
Result Date: 12/24/2022
Order Number: SO00000

ORDERING PHYSICIAN

Physician: Dr. John Smith
Clinic: Alaska Urology
Address: 123 Snow Storm Street
Anchorage, AK 12345



RANGES

Low Risk: 0% – 5.4%
Elevated Risk: ≥ 5.5%

RISK ASSESSMENT FACTORS*

Age: 67
Family History: Yes
African Ancestry: No
Abnormal DRE: No
Previous Biopsy: Yes
PSA: 11.0 ng/mL
Prostate Volume: 39 cc
PSA Density: 0.28 ng/mL/cc

*Risk Assessment Factors are included in the calculation of MPS2 when their inclusion increases the diagnostic accuracy of the results.

Risk category: Low

Likelihood of Clinically Significant Cancer Grade Group 2 or higher: 2.7%

Test Description:

MyProstateScore 2.0 (MPS2) measures 18 urinary biomarkers* to predict the percent likelihood of detecting clinically-significant prostate cancer (Grade Group [GG] ≥2, also termed Gleason score ≥7) on biopsy. For those who are biopsy naïve, a score of >7.5% is reported as elevated risk. For those patients with a prior negative biopsy, a score of >5.4% is reported as elevated risk.

*T2:ERG, SCHLAP1, OR51E2, APOC1, PCAT14, CAMKK2, PCA3, NKAIN1, B3GNT6, TFF3, SPON2, PCGEM1, TRGV9, TMSB15A, ERG, KLK3, KLK4, HOXC6

Disclaimer:

This test was developed, and its performance characteristics determined by Lynx Dx, Inc. This test is intended to assist clinical decision making related to the need for a prostate biopsy. Definitive diagnosis of prostate cancer can only be confirmed through a prostate biopsy. This test has not been cleared nor approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendment of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing.

CLIA Director: Dr. John Kitchen; CLIA Number: 23D2182199

Performing site: Lynx Dx, Inc., 5230 S. State Rd., Ann Arbor, MI 48108

PATIENT

Name: Lynx Dx Patient
DOB: 04/19/1965
MRN: REQ000000

SPECIMEN

Collection Date: 10/21/2022
Receive Date: 10/23/2022
Result Date: 10/28/2022
Order Number: SO00000

ORDERING PHYSICIAN

Physician: Dr. John Smith
Clinic: Alaska Urology
Address: 123 Snow Storm Street
Anchorage, AK 12345


RANGES

Low Risk: 0% – 5.4%
Elevated Risk: ≥ 5.5%

RISK ASSESSMENT FACTORS*

Age: 57
Family History: No
African Ancestry: No
Abnormal DRE: No
Previous Biopsy: Yes
PSA: 6.0 ng/mL
Prostate Volume: 37 cc
PSA Density: 0.16 ng/mL/cc

*Risk Assessment Factors are included in the calculation of MPS2 when their inclusion increases the diagnostic accuracy of the results.



Risk category: Elevated

Likelihood of Clinically Significant Cancer Grade Group 2 or higher: 30.5%

Test Description:

MyProstateScore 2.0 (MPS2) measures 18 urinary biomarkers* to predict the percent likelihood of detecting clinically-significant prostate cancer (Grade Group [GG] ≥2, also termed Gleason score ≥7) on biopsy. For those who are biopsy naïve, a score of >7.5% is reported as elevated risk. For those patients with a prior negative biopsy, a score of >5.4% is reported as elevated risk.

*T2:ERG, SCHLAP1, OR51E2, APOC1, PCAT14, CAMKK2, PCA3, NKAIN1, B3GNT6, TFF3, SPON2, PCGEM1, TRGV9, TMSB15A, ERG, KLK3, KLK4, HOXC6

Disclaimer:

This test was developed, and its performance characteristics determined by Lynx Dx, Inc. This test is intended to assist clinical decision making related to the need for a prostate biopsy. Definitive diagnosis of prostate cancer can only be confirmed through a prostate biopsy. This test has not been cleared nor approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendment of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing.

CLIA Director: Dr. John Kitchen; CLIA Number: 23D2182199

Performing site: Lynx Dx, Inc., 5230 S. State Rd., Ann Arbor, MI 48018